PTGDS and Duchenne muscular dystrophy: Other targets that do not involve dystrophin production or the different aforementioned steroid therapies are also being explored: TAS-205, a drug that blocks hematopoietic prostaglandin D synthase, could limit inflammation in DMD and subjects are currently being recruited for a phase-3 study.